作为一线抗疟药，以青蒿素(ART)为基础的联合疗法(ACTs)已在东南亚和非洲出现抗性，我们前期研究与临床观察也支持该观点。若能逆转ART及其衍生物抗性将为疟疾防治提供一种解决方案。本课题拟以恶性疟原虫为研究对象，体外培育双氢青蒿素(DHA)抗性系；以体外药敏试验结合细胞毒性试验筛选作用于DHA抗性株多药耐药蛋白1的抑制剂；以人脑微血管内皮细胞膜为材料，包封DHA和抑制剂，构建纳米给药体系，靶向作用于DHA抗性株的感染红细胞以达到逆转DHA抗性之目的。该项目的实施将为解决恶性疟原虫ART抗性提供科学依据，具有重要的理论意义和社会意义。

As the first-line antimalarial drug, Artemisinin (ART) -based combination therapy (ACTs) has emerged resistance in Southeast Asia and Africa. Our previous study and clinical observations support this view. Reversal of ART and its derivatives resistance in Plasmodium falciparum is an effective strategy for malaria control. In this study, dihydroartemisinin (DHA)-resistant lines of P. falciparum are induced and cultured in vitro. The inhibitor targeting multidrug resistance protein 1 in P. falciparum dihydroartemisinin (DHA)-resistant lines is screened by susceptibility testing and cytotoxicity test in vitro. Then, nanoscaled antimalarial carrier system containing DHA and optimized inhibitor is constructed based on the membrane of cultured human vascular endothelial cells (ECs). Reversal of DHA resistance in infected erythrocytes of P. falciparum DHA resistant strains by the targeting drug delivery system is evaluated in vitro. It offers a scientific solution to resolving the ART resistance of P. falciparum, which has important theoretical and social significance.